Reading Your Panel
You got your lab results back and it looks like a foreign language. Abbreviations, decimal points, reference ranges that span enormous gaps, and arrows pointing up or down. Your provider will review these with you, but understanding your own numbers puts you in control of your health. This guide breaks down every marker on a standard TRT monitoring panel in plain language.
Testosterone Markers
Total Testosterone measures all testosterone in your blood, both bound and free. The target range on TRT is typically 500-800 ng/dL, measured at trough, which is the lowest point in your injection cycle, usually the morning before your next dose. If your trough is above 800, your dose may be too high. If it is below 500, your dose may need adjustment.
Free Testosterone is the 2-3% of testosterone that is unbound and biologically active. This is arguably more important than total because it is what your body actually uses. Target range is 15-25 pg/mL.
Estradiol (E2) is an estrogen produced from testosterone via aromatase. Some estradiol is necessary and beneficial. Too much causes water retention, mood changes, and gynecomastia. Too little causes joint pain, low libido, and mood issues. Target range on TRT is typically 20-40 pg/mL. Sensitive assay is recommended for accurate male ranges.
SHBG binds testosterone and makes it unavailable. If SHBG is high, you may need a higher dose or more frequent injections to maintain adequate free testosterone. If low, your free T may be higher than total suggests.
Ready to put numbers behind it?
At-home lab kit, licensed provider review, and a protocol that's actually built around your labs โ not a template.
Decode every number on your lab report
The 7 biomarkers every man over 30 should track โ and what their numbers actually mean. 8 pages, instant download.
Get the Free GuideMetabolic and Safety Markers
Hematocrit and Hemoglobin measure red blood cell concentration. Testosterone stimulates erythropoiesis, which can raise hematocrit above the normal range. Hematocrit above 54% increases blood viscosity and warrants intervention, either dose reduction, more frequent lower doses, or therapeutic phlebotomy. This is the most common side effect requiring monitoring.
PSA (Prostate-Specific Antigen) screens for prostate issues. A baseline is established before starting TRT, and any rise of more than 1.4 ng/mL from baseline within 12 months warrants urological evaluation. Absolute levels above 4.0 should be investigated.
Lipid Panel tracks cholesterol and triglycerides. TRT can modestly lower HDL in some men while improving triglycerides and overall metabolic profile.
Liver Function (AST, ALT) monitors liver health. Oral testosterone products can stress the liver, but injectable testosterone cypionate has minimal liver impact.
Metabolic Panel (glucose, A1C) tracks blood sugar. TRT typically improves insulin sensitivity and may lower fasting glucose over time.
Red Flags to Watch
During TRT monitoring, alert your provider immediately if hematocrit exceeds 54%, PSA rises more than 1.4 points from baseline within a year, you develop significant breast tenderness or enlargement, blood pressure rises significantly, or you experience mood changes that feel disproportionate to your dose. These are not emergencies but require prompt evaluation and potential protocol adjustment.
Optimal vs Reference Ranges
Lab reports show reference ranges designed for the general population. On TRT, your targets are different and more specific than population norms. Work with your provider to understand your personal targets rather than simply aiming for within range on the lab report. The goal is symptom resolution with markers in safe zones, not just passing the test.
This article is informed by peer-reviewed research and clinical guidelines:
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 2023;389:107-117. View study →
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018;200:423-432. View guideline →
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1715-1744. View guideline →
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men (Testosterone Trials). N Engl J Med 2016;374:611-624. View study →
All Heyday Health content is reviewed by licensed providers and updated when clinical guidelines change. See our medical team for review credentials.